New NAFTA terms put hold on Canadian drug prices
December 11, 2019Research and Development, Sales and Marketing Canada, NAFTA, US, pharma
NAFTA members have agreed to remove a provision that would have increased protections on biologics drugs. This means Canada, despite …
Multiple sclerosis market to be worth $32.9bn in 2028
December 11, 2019Research and Development Big Pharma, MS, MS treatement, multiple sclerosis, pharma
The multiple sclerosis (MS) market is expected to see a growth in sales, and increase from $19.8 billion in 2018 …
Correvio’s atrial fibrillation drug voted down by FDA committee over safety concerns
December 11, 2019Research and Development, Sales and Marketing Correvio Pharma, FDA, atrial fibrillation, pharma
It has emerged that Correvio Pharma’s anti-arrhythmic therapy Brinavess was shot down by the FDA’s Cardiovascular and Renal Drugs Advisory …
27,000 chickens to be culled after UK bird flu outbreak
December 11, 2019Research and Development Bird Flu, Chicken Flu, Swin Flu, influenza, influenza b
A chicken farm in Suffolk has been confirmed by the British government to have cases of bird flu. 27,000 birds …
Bristol-Myers Squibb drug boasts strong overall survival in acute myeloid leukaemia
December 11, 2019Research and Development ASH 19, Bristol-Myers Squibb, acute myeloid leukaemia, pharma
Bristol-Myers Squibb took the opportunity at the 2019 American Society of Hematology (ASH) Annual Meeting to reveal new efficacy data …
Takeda commits to advancing treatments for rare bleeding disorders and cancer
December 10, 2019Manufacturing and Production, Research and Development ASH 19, Cancer, Takeda, lymphoma, oncology
Takeda presented at the 61st American Society of Hematology (ASH) Annual Meeting, 29 company-sponsored abstracts to highlight its commitment to …
MSD set to acquire ArQule in deal worth up to $2.7 billion
December 10, 2019Manufacturing and Production, Medical Communications, Sales and Marketing MSD, acquisition, arqule, pharma
MSD has revealed its intention to acquire biopharma firm ArQule in a deal worth a potential total of $2.7 billion, …
Sanofi to move away from diabetes and cardiovascular, as company shakeup continues
December 10, 2019Manufacturing and Production ASH 19, Sanofi, Sanofi Diabetes, Sanofi Insulin, diabetes, insulin
Sanofi has said it will stop investment and research into creating new diabetes and cardiovascular drugs, as part of the …
South Korea jails executives for their role in Samsung Biologics fraud
December 10, 2019Manufacturing and Production Samsung phones, Sanofi, Sanofi Diabetes, South Korea Healthcare System, South Korea Samsung, diabetes, inhaled insulin, insulin, south korea
Three executives of Samsung Electronics have been sentenced to jail for their role in committing fraud at its biotech affiliate …
Janssen’s Darzalex combo shows strong overall survival benefit at ASH 2019
December 10, 2019Manufacturing and Production, Research and Development ASH 19, Janssen, darzalex, pharma
Janssen has unveiled new Phase 3 data on the efficacy of Darzalex (daratumumab) when combined with bortezomib, melphalan and prednisone …
Pfizer and Sangamo’s haemophilia gene therapy shows increased factor VIII levels
December 9, 2019Manufacturing and Production, Sales and Marketing American Society of Hematology, Pfizer, Sangamo Therapeutics, hematology
Pfizer and Sangamo Therapeutics have revealed that their investigational gene therapy, SB-525, sustained increased factor VIII (FVIII) levels in patients …
Johnson & Johnson to support Rwanda’s preparations against Ebola outbreak
December 9, 2019Sales and Marketing Ebola, Ebola Guniea, Ebola virus
Johnson & Johnson will provide up to 200,000 Ebola vaccines to the Republic of Rwanda, through its pharmaceutical subsidiary Janssen. …
Strong four-year follow-up data revealed for AbbVie’s venetoclax combo in chronic lymphocytic leukaemia
December 9, 2019Research and Development, Sales and Marketing ASH 2019, AbbVie, chronic lymphocytic leukaemia, pharma, venetoclax
AbbVie used the platform of the American Society of Hematology (ASH) conference to present four-year follow-up analysis data on venetoclax …
AstraZeneca’s trial of leukaemia drug Calquence yields positive results
December 9, 2019Sales and Marketing AstraZeneca, Calquence, leukaemia, phase 3
AstraZeneca confirmed it had recorded positive results from its Phase 3 trial of Calquence plus obinutuzumab in leukaemia. The trial …
Sanofi acquires biotech firm Synthorx for $2.5 billion
December 9, 2019Sales and Marketing Genetic Alphabet, Sanofi, acute lymphoblastic leukaemia, leukaemia
Sanofi has agreed to buy California-based biotechnology firm Synthrox, in a deal worth about $2.5 billion (£1.95 billion). Paul Hudson, …
Transactions in the pharma sector: Through the EU merger review looking-glass
December 9, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EU, feature, mergers & acquisitions, pharma
With mergers and acquisitions back in full swing after a period of drought, Alec Burnside (Partner) and Delphine Strohl (Associate) …
J&J’s CAR-T candidate boasts 100% response rate in relapsed or refractory multiple myeloma
December 9, 2019Research and Development, Sales and Marketing ASH 2019, CAR-T, J&J, JJ, Johnson & Johnson, pharma
Johnson & Johnson were present at the American Society of Hematology (ASH) Annual Meeting over the weekend to unveil new …
FDA investigating if carcinogen NDMA is in diabetes drug
December 6, 2019Medical Communications FDA, Health Canada, MDMA, NDMA, carcinogen, diabetes
The FDA is looking into if the diabetes drug metformin has unsafe levels of a cancer-causing chemical. This comes after …
Sage Therapeutics’ depression drug falls short at Phase 3
December 6, 2019Medical Communications, Research and Development Sage Therapeutics, major depressive disorder, pharma, trial failure
Sage Therapeutics has announced that its candidate SAGE-217 flopped in Phase 3 trials investigating its efficacy in symptom reduction for …
Anti-vaxx movement complicit in 140,000 global measles deaths in 2018, mostly in children
December 6, 2019Medical Communications anti vaxx, anti-vaxx, anti-vaxxers, measles mumps polio, measls, mumps, polio, vaccinations, vaccines
Over 140,000 people died from measles last year, with most of them being children under five, according to World Health …
Latest content
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board
